Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.
The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China.
Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 24 | -0.19 Increased by +32.14% | -0.25 Increased by +24.00% |
| Mar 28, 24 | -0.20 Increased by +23.38% | -0.25 Increased by +20.32% |
| Nov 14, 23 | -0.23 Increased by +11.54% | -0.29 Increased by +20.69% |
| Aug 10, 23 | -0.20 Decreased by -5.26% | -0.31 Increased by +35.48% |
| May 15, 23 | -0.28 Decreased by -40.00% | -0.30 Increased by +6.67% |
| Mar 16, 23 | -0.26 Decreased by -73.33% | -0.28 Increased by +7.14% |
| Nov 14, 22 | -0.26 Decreased by -18.18% | -0.21 Decreased by -23.81% |
| Aug 11, 22 | -0.19 Increased by +29.63% | -0.20 Increased by +5.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 56.00 K Increased by 0.00% | -4.18 M Increased by +22.70% | Decreased by -7.47 K% Increased by +22.70% |
| Dec 31, 23 | 56.00 K Increased by 0.00% | -4.18 M Increased by +16.32% | Decreased by -7.47 K% Increased by +16.32% |
| Sep 30, 23 | 57.00 K Increased by 0.00% | -4.74 M Increased by +8.07% | Decreased by -8.31 K% Increased by +8.07% |
| Jun 30, 23 | 57.00 K Increased by 0.00% | -4.25 M Decreased by -8.20% | Decreased by -7.46 K% Decreased by -8.20% |
| Mar 31, 23 | 56.00 K Increased by 0.00% | -5.41 M Decreased by -31.64% | Decreased by -9.67 K% Decreased by -31.64% |
| Dec 31, 22 | 56.00 K Increased by 0.00% | -5.00 M Decreased by -32.84% | Decreased by -8.93 K% Decreased by -32.84% |
| Sep 30, 22 | 57.00 K Increased by 0.00% | -5.16 M Decreased by -49.29% | Decreased by -9.04 K% Decreased by -49.29% |
| Jun 30, 22 | 57.00 K Increased by 0.00% | -3.93 M Increased by +7.16% | Decreased by -6.89 K% Increased by +7.16% |